Skip to main content
. Author manuscript; available in PMC: 2023 Jan 24.
Published in final edited form as: Biochem Pharmacol. 2019 Mar 29;167:27–32. doi: 10.1016/j.bcp.2019.03.037

Fig. 7.

Fig. 7.

Effect of PARP inhibitor (olaparib) on proliferation and viability of HepG2 cells (A) Proliferation of HepG2 cells was determined at 24 h, 48 h and 72 h without or with olaparib. (B) Cell viability was calculated by dividing the number of cells that did not stain with trypan blue by the total number of cells. Cells were counted with hemocytometer. The result is the means ± standard deviations from two independent experiments. Start; 1.0 × 105 cells/3.5 cm dish (represented as 100%). Significances were 0 μM vs. 10 μM olaparib, 0 μM vs. 30 μM olaparib, 0 μM vs. 50 μM olaparib. *p < 0.05, **p < 0.01.